Related Experiment Video
Updated: Jan 9, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Brensocatib: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
None:
Brensocatib (BRINSUPRI™), an oral, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), is being developed by Insmed Incorporated under license from AstraZeneca for the treatment of neutrophil-mediated diseases, including non-cystic fibrosis bronchiectasis (NCFB), chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). Brensocatib received its first approval on 12 August 2025 in the USA for the treatment of NCFB in adult and paediatric patients 12 years of age and older. Brensocatib received a positive opinion in the EU on 17 Oct 2025 and is also under regulatory review in the UK for this indication. This article summarizes the milestones in the development of brensocatib leading to this first approval for the treatment of NCFB.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Therapeutic Drug Monitoring: Overview and Classification
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

